PACS Group, Inc.

PACS

HealthcareSmall CapUS Equities · NYSE / NASDAQ

AI Agents

Company Profile

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. The company engages in the acquisition, ownership, and leasing of health care-related properties. PACS Group, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Valuation

Market Cap$5.9B

Current Price$37.91as of Jun 23, 2026

P/E Ratio30.96

P/B Ratio6.26

EV / EBITDA24.98

EV / Sales1.74

Profitability

Operating Margin5.9%

Net Profit Margin3.6%

EBITDA Margin7.0%

Returns

ROE20.2%

ROCE24.1%

ROIC %5.0%

ROA3.4%

Solvency

Current Ratio1.07

Debt / Equity3.67

Debt / Assets0.62

CFO / Net Profit2.11

Price History▲ 197.33% over 1Y

Technical Chart

Historical Performance Charts

5-year financial trends. Figures in USD millions.

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Latest fiscal year: 2025

Revenue$5.3B▲ 29.3%

EBITDA$368M▲ 97.4%

Net Profit$192M▲ 243.5%

Cash from Ops (CFO)$404M▲ 10.0%

Free Cash Flow (FCF)$155M▲ 784.5%

Revenue CAGR 3Y29.7%

Revenue CAGR 5Y-

Net Profit CAGR 3Y8.4%

Net Profit CAGR 5Y-

Historical Growth

Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)

Year	Revenue	EBITDA	Net Profit	FCF	ROE	Rev Growth 1Y	NP Growth 1Y
2025	$5.3B	$368M	$192M	$155M	20.2%	29.3%	243.5%
2024	$4.1B	$187M	$56M	$18M	7.9%	31.4%	-50.6%
2023	$3.1B	$233M	$113M	$-109M	117.4%	28.5%	-25.0%
2022	$2.4B	$255M	$150M	$14M	236.5%	-	-
2021	-	-

Financial Statements

Income statement, balance sheet, and cash flow as reported

Consolidated Figures in USD Millions.

Metric	2021	2022	2023	2024	2025
Total Revenue	-	2,421.99	3,111.49	4,089.73	5,288.93
Operating Revenue	-	2,399.16	3,110.11	4,086.66	5,287.88
Cost Of Revenue	-	2,021.32	2,664.42	3,582.04	4,508.60
Gross Profit	-	400.68	447.07	507.69	780.33
Operating Expense	-	171.32	239.30	384.62	470.73
Selling General And Administration	-	149.01	213.66	343.81	415.07
Total Expenses	-	2,192.63	2,903.72	3,966.66	4,979.34
Operating Income	-	229.36	207.77	123.07	309.60
Total Operating Income As Reported	-	229.36	207.77	123.07	309.60
EBITDA	-	254.89	232.87	186.70	368.48
Normalized EBITDA	-	254.89	232.87	178.66	368.48
EBIT	-	232.58	207.24	145.90	312.81
Interest Expense	-	25.54	49.92	44.34	28.36
Net Interest Income	-	-25.54	-49.92	-44.34	-28.36
Other Non Operating Income Expenses	-	3.22	-0.54	14.78	3.22
Other Income Expense	-	3.22	-0.54	22.82	3.22
Interest Expense Non Operating	-	25.54	49.92	44.34	28.36
Net Non Operating Interest Income Expense	-	-25.54	-49.92	-44.34	-28.36
Pretax Income	-	207.04	157.32	101.55	284.45
Tax Provision	-	56.55	44.44	46.21	92.99
Tax Rate For Calcs	-	0	0	0	0
Tax Effect Of Unusual Items	-	0	0	1.69	0
Net Income Continuous Operations	-	150.50	112.88	55.34	191.46
Net Income From Continuing And Discontinued Operation	-	150.50	112.87	55.76	191.54
Net Income From Continuing Operation Net Minority Interest	-	150.50	112.87	55.76	191.54
Net Income	-	150.50	112.87	55.76	191.54
Net Income Common Stockholders	-	150.50	112.87	55.76	191.54
Net Income Including Noncontrolling Interests	-	150.50	112.88	55.34	191.46
Normalized Income	-	150.50	112.87	49.40	191.54
Diluted NI Availto Com Stockholders	-	150.50	112.87	55.76	191.54
Basic Average Shares	-	150.15	147.77	146.66	156.18
Diluted Average Shares	-	150.15	147.77	148.57	156.70
Reconciled Depreciation	-	22.31	25.63	40.81	55.66
Reconciled Cost Of Revenue	-	2,021.32	2,664.42	3,582.04	4,508.60
Total Unusual Items	-	0	0	8.05	0
Total Unusual Items Excluding Goodwill	-	0	0	8.05	0
Minority Interests	-	0	-0.01	0.42	0.08
Special Income Charges	-	0	0	8.05	0
Other Special Charges	-	-	-	-8.05	-
Depreciation Amortization Depletion Income Statement	-	22.31	25.63	40.81	55.66
Depreciation And Amortization In Income Statement	-	22.31	25.63	40.81	55.66
General And Administrative Expense	-	149.01	213.66	343.81	415.07
Other Gand A	-	149.01	213.66	343.81	415.07
Rent Expense Supplemental	-	160	216.71	284.95	378.91

Peer Comparison

Healthcare sector peers, ranked by market cap

Company	Ticker	Market Cap	P/E	P/B	ROE	EV/EBITDA
PACS Group, Inc.this co.	PACS	$5.9B	30.96	6.26	20.2%	24.98
Kymera Therapeutics, Inc.	KYMR	$6.1B	-	3.89	-19.7%	-
Terns Pharmaceuticals, Inc.	TERN	$6.1B	-63.58	6.08	-9.6%	-51.02
Rhythm Pharmaceuticals, Inc.	RYTM	$6.0B	-	22.25	-74.8%	-
Mirum Pharmaceuticals, Inc.	MIRM	$5.6B

Learn while you research

Hand-picked academy chapters to deepen your understanding of PACS Group, Inc. and the metrics that matter.

01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read 02 Valuation Multiples Explained

Loading…

Year

Revenue

EBITDA

Net Profit

FCF

ROE

Rev Growth 1Y

NP Growth 1Y

2025

$5.3B

$368M

$192M

$155M

20.2%

29.3%

243.5%

2024

$4.1B

$187M

$56M

$18M

7.9%

31.4%

-50.6%

2023

$3.1B

$233M

$113M

$-109M

117.4%

28.5%

-25.0%

2022

$2.4B

$255M

$150M

$14M

236.5%

2021

Metric

2021

2022

2023

2024

2025

Total Revenue

2,421.99

3,111.49

4,089.73

5,288.93

Operating Revenue

2,399.16

3,110.11

4,086.66

5,287.88

Cost Of Revenue

2,021.32

2,664.42

3,582.04

4,508.60

Gross Profit

400.68

447.07

507.69

780.33

Operating Expense

171.32

239.30

384.62

470.73

Selling General And Administration

149.01

213.66

343.81

415.07

Total Expenses

2,192.63

2,903.72

3,966.66

4,979.34

Operating Income

229.36

207.77

123.07

309.60

Total Operating Income As Reported

229.36

207.77

123.07

309.60

EBITDA

254.89

232.87

186.70

368.48

Normalized EBITDA

254.89

232.87

178.66

368.48

EBIT

232.58

207.24

145.90

312.81

Interest Expense

25.54

49.92

44.34

28.36

Net Interest Income

-25.54

-49.92

-44.34

-28.36

Other Non Operating Income Expenses

3.22

-0.54

14.78

3.22

Other Income Expense

3.22

-0.54

22.82

3.22

Interest Expense Non Operating

25.54

49.92

44.34

28.36

Net Non Operating Interest Income Expense

-25.54

-49.92

-44.34

-28.36

Pretax Income

207.04

157.32

101.55

284.45

Tax Provision

56.55

44.44

46.21

92.99

Tax Rate For Calcs

Tax Effect Of Unusual Items

1.69

Net Income Continuous Operations

150.50

112.88

55.34

191.46

Net Income From Continuing And Discontinued Operation

150.50

112.87

55.76

191.54

Net Income From Continuing Operation Net Minority Interest

150.50

112.87

55.76

191.54

Net Income

150.50

112.87

55.76

191.54

Net Income Common Stockholders

150.50

112.87

55.76

191.54

Net Income Including Noncontrolling Interests

150.50

112.88

55.34

191.46

Normalized Income

150.50

112.87

49.40

191.54

Diluted NI Availto Com Stockholders

150.50

112.87

55.76

191.54

Basic Average Shares

150.15

147.77

146.66

156.18

Diluted Average Shares

150.15

147.77

148.57

156.70

Reconciled Depreciation

22.31

25.63

40.81

55.66

Reconciled Cost Of Revenue

2,021.32

2,664.42

3,582.04

4,508.60

Total Unusual Items

8.05

Total Unusual Items Excluding Goodwill

8.05

Minority Interests

-0.01

0.42

0.08

Special Income Charges

8.05

Other Special Charges

-8.05

Depreciation Amortization Depletion Income Statement

22.31

25.63

40.81

55.66

Depreciation And Amortization In Income Statement

22.31

25.63

40.81

55.66

General And Administrative Expense

149.01

213.66

343.81

415.07

Other Gand A

149.01

213.66

343.81

415.07

Rent Expense Supplemental

160

216.71

284.95

378.91

Company

Ticker

Market Cap

P/E

P/B

ROE

EV/EBITDA

PACS Group, Inc.this co.

PACS

$5.9B

30.96

6.26

20.2%

24.98

Kymera Therapeutics, Inc.

KYMR

$6.1B

3.89

-19.7%

Terns Pharmaceuticals, Inc.

TERN

$6.1B

-63.58

6.08

-9.6%

-51.02

Rhythm Pharmaceuticals, Inc.

RYTM

$6.0B

22.25

-74.8%

Mirum Pharmaceuticals, Inc.

MIRM

$5.6B

PACS Group, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

PACS Group, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Key concepts to brush up on